Evelo Biosciences, Inc.
EVLODelisted Dec 27, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001694665
Evelo Biosciences, Inc. was delisted on Dec 27, 2023; its insiders filed their last Form 4 on Nov 8, 2023; 29 institutions reported holding it in 13F filings for Q3 2023, worth $52.0M in total; no superinvestor held it.
Q1 2023 vs. Q4 2022
How the institutions holding Evelo Biosciences, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 44 | 39 | −5 |
| Shares | 87.0M | 85.7M | −1.29M (−1.5%) |
| Value | $140.1M | $15.5M | −$124.6M (−88.9%) |
New holders (5)
Institutions that held Evelo Biosciences, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jefferies Financial Group Inc. | 75,000 | $13.6K | 0.00% |
| Virtu Financial LLC | 24,337 | $4.00K | 0.00% |
| Avantax Planning Partners, Inc. | 15,000 | $2.71K | 0.00% |
| Affinity Capital Advisors, LLC | 10,595 | $1.92K | 0.00% |
| Simplex Trading, LLC | 1,469 | $0 | 0.00% |
Sold out (10)
Institutions that held Evelo Biosciences, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| 683 Capital Management, LLC | 90,291 | $145.4K |
| Bessemer Group Inc | 61,289 | $99.0K |
| Boothbay Fund Management, LLC | 52,699 | $84.8K |
| Man Group plc | 52,637 | $84.7K |
| Charles Schwab Investment Management Inc | 31,345 | $50.5K |
| Qube Research & Technologies Ltd | 29,537 | $47.6K |
| Shay Capital LLC | 18,511 | $29.8K |
| Balyasny Asset Management LLC | 10,135 | $16.3K |
| Citadel Advisors LLC | 9,952 | $16.0K |
| Fairfield Financial Advisors, LTD | 1,075 | $1.73K |